The finding that antibody sialylation can suppress inflammation provides new opportunities for drug development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tanner, J.F. Cancer Metastasis Rev. 24, 585–598 (2005).
Kaneko, Y., Nimmerjahn, F. & Ravetch, J.V. Science 313, 670–673 (2006).
Deisenhofer, J. Biochemistry 20, 2361–2370 (1981).
Jefferis, R. Biotechnol. Prog. 21, 11–16 (2005).
Nimmerjahn, F. & Ravetch, J.V. Immunity 24, 19–28 (2006).
Hamilton et al. Science 313, 1441–1443 (2006).
Niwa, R. et al. J. Immunol. Meth. 306, 151–160 (2006).
Ferrara, C. et al. Biotechnol. Bioeng. 93, 851–861 (2006).
Sondermann, P. et al. Nature 406, 267–273 (2003).
Krapp, S. et al. J. Mol. Biol. 325, 979–989 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jefferis, R. A sugar switch for anti-inflammatory antibodies. Nat Biotechnol 24, 1230–1231 (2006). https://doi.org/10.1038/nbt1006-1230
Issue Date:
DOI: https://doi.org/10.1038/nbt1006-1230